Our aim is to synthesize and critically appraise the current preclinical and clinical evidence supporting GPC3-targeted imaging and therapeutic approaches in HCC, highlighting key achievements, ongoing challenges, and opportunities for future innovation. Here, GPC3 is linked to hepatocellular carcinoma.